Article
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
Cancer - 15 May 2013
Fury Matthew G, Sherman Eric, Ho Alan L, Xiao Han, Tsai Frank, Nwankwo Oby, Sima Camelia, Heguy Adrian, Katabi Nora, Haque Sofia, Pfister David G
Abstract excerpt
BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy. The authors conducted a phase 1 study to evaluate the addition of oral everolimus to cisplatin and docetaxel as induction chemotherapy for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.